Q1 2025 Cryoport Inc Earnings Call Transcript
Key Points
- CryoPort Inc (CYRX) reported a solid start to the year with $41 million in revenue from continuing operations, marking a 10% year-over-year growth.
- The strategic partnership with DHL is expected to enhance CryoPort Inc (CYRX)'s positioning in Asia Pac and EMEA, leveraging DHL's global scale.
- Life Sciences Services revenue increased by 17% year over year, driven by the commercialization of Cell & Gene therapies, which grew 33% over the previous year.
- CryoPort Inc (CYRX) supported 19 commercial therapies and 711 clinical trials, representing approximately 70% of Cell & Gene therapy trials.
- The company confirmed its revenue guidance for fiscal year 2025 in the range of $165 million to $172 million, indicating confidence in its growth forecast.
- The financials of CRYOPDP, previously part of CryoPort Inc (CYRX)'s Life Sciences Services segment, are now presented as discontinued operations due to its sale to DHL.
- Tariffs on raw materials like aluminum are beginning to impact costs, although CryoPort Inc (CYRX) plans to implement surcharges to mitigate this.
- The company faces potential challenges from global tariffs, which could affect the cost of raw materials and supply chain dynamics.
- Despite revenue growth, CryoPort Inc (CYRX) is still working towards achieving positive adjusted EBITDA during 2025.
- The market environment remains uncertain, with potential impacts from government actions such as drug pricing regulations and the Inflation Reduction Act.
Good afternoon, and welcome to Cryoport first-quarter 2025 earnings call. (Operator Instructions) As a reminder, this call is being recorded.
I will now turn the call over to your host, Todd Fromer from KCSA Strategic Communications. Please go ahead, sir.
Thank you. Before we begin today, I would like to remind everyone that this conference call contains certain forward-looking statements. All statements that address our operating performance, events or developments that we expect or anticipate occurring in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and not on information currently available to our management team. Our management team believes that these forward-looking statements are reasonable as and when made.
However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
